EN
科学研究

Metabolic Diseases.png

Boyle, JG, et al., Clinical Science (2018) 132 1699–1709


图片1.png





学术发表

标题 发表场所 类型 时间
ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in NHP model and 91% more relative weight loss than petrelintide in DIO rat model 第33届欧洲肥胖症大会
（ECO 2026）		 海报 5/2026
ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, demonstrated 14-day average observed half-life, 6-fold longer than tirzepatide, in NHP model and 71% more relative weight loss than tirzepatide in DIO mouse model 第33届欧洲肥胖症大会
（ECO 2026）		 海报 5/2026
ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy 第33届欧洲肥胖症大会
（ECO 2026）		 海报 5/2026
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study 第61届欧洲糖尿病研究协会
（EASD 2025）		 简短口头报告 9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model 美国糖尿病协会第85届科学会议
（ADA 2025）		 海报 6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study 美国糖尿病协会第85届科学会议
（ADA 2025）		 海报 6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study 第32届欧洲肥胖症大会 （ECO 2025） 引导型海报 5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice 第32届欧洲肥胖症大会 （ECO 2025） 口头报告 5/2025

  • © 2018 Ascletis Pharma Inc.

contact

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1